Tech Company Financing Transactions
Oncorus Funding Round
Oncorus secured a $57 million Series A venture capital round on 7/20/2016. Investors included MPM Capital, Celgene and Deerfield Capital.
Transaction Overview
Company Name
Announced On
7/20/2016
Transaction Type
Venture Equity
Amount
$57,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds from the Series A financing round will be used to advance Oncorus's immunotherapy platform using its next-generation oncolytic herpes simplex virus (oHSV).
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
50 Hampshire St. 401
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Oncorus, Inc. (Nasdaq: ONCR) is a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses to treat several types of cancer, including highly malignant and aggressive cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Theodore Ashburn
Chief Scientific Officer
Christophe Quéva
Vice President
Lorena Lerner
VP - Bus. Development
Stephanie Duncanson
VP - Bus. Development
John Goldberg
VP - Operations
Brett Belongia
Browse more venture capital transactions:
Prev: 7/20/2016: Synthorx venture capital transaction
Next: 7/20/2016: Pantheon venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs